To report a case of transformation from lung adenocarcinoma to pulmonary giant cell carcinoma (PGCC) after resistance to targeted therapy and analyze possible mechanisms.
Approach:
Case Description: A 71-year-old male with lung adenocarcinoma and KRAS G12C mutation developed resistance to sotorasib-targeted therapy, leading to a diagnosis of PGCC after re-biopsy.
Literature Review: The case was combined with a literature review to explore the mechanisms of transformation and the importance of re-biopsy after targeted therapy resistance.
Key Findings:
PGCC is a rare and highly malignant subtype of lung cancer, accounting for less than 1% of cases.
The patient had a history of lung adenocarcinoma with a KRAS G12C mutation and developed PGCC after targeted therapy resistance.
Re-biopsy confirmed the transformation to PGCC.
Interpretation:
Limitations:
The findings are based on a single case report, limiting generalizability.
Further studies are needed to understand the mechanisms of transformation and clinical outcomes.
